A single-arm, phase Ib-II trial of pembrolizumab (PD-1 inhibitor) plus trastuzumab (HER2 inhibitor) also demonstrated activity and durable clinical benefit in patients with PD-L1-positive, trastuzumab-resistant, advanced, HER2-positive breast cancer [3]. Here, CD274 is linked to breast carcinoma.